NO (nitric oxide) to priapism with hydroxyurea and tadalafil
Abstract
In this issue of Blood, Idris et al 1 have demonstrated the feasibility of conducting a trial to prevent priapism in male patients with sickle cell anemia and provide data that suggest a benefit for hydroxyurea in reducing the rate of priapism.Clinical complications of sickle cell disease (SCD) are caused by vaso-occlusion with ischemia-reperfusion injury and hemolytic anemia. 2 Hemolysis is associated not only with anemia and cholelithiasis but also with vasculopathic complications such as stroke, pulmonary hypertension, kidney disease, leg ulcers, and priapism.
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
- Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent
- Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review
- Molecular Docking of Silymarin as a Ligand for Aromatase Enzyme and HIV-1 Reverse Transcriptase Using Molegro Virtual Docker
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.